MALVERN, Pa., Nov. 24, 2025 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD), today announced two presentations at the 18th Clinical Trials on Alzheimer's Disease (CTAD) conference, taking place December 1-4, 2025 in San Diego, California. The presentations will highlight progress across the Alzheimer’s an ...

MALVERN, Pa., Nov. 18, 2025 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD), today announced that the U.S. Food and Drug Administration (FDA) has scheduled a Type C meeting in January 2026 to discuss the Company's pathway for Parkinson's disease dementia (PDD). Annovis also reaffirmed that its ongoing Pha ...

Small Cap Annovis Bio Inc. (NYSE:ANVS) stock is trading higher on Monday, with a session volume of 12.29 million compared to the average volume of 615.12 thousand as per data from Benzinga Pro.A late-stage clinical drug platform company focused on neurodegenerative diseases such as Alzheimer’s disease and Parkinson’s disease, revealed new data demonstrating the impact of amyloid co-pathology on cognitive outcomes in Parkinson’s patients and the therapeutic efficacy of buntanetap.In the Phase 3 study in earl ...

Buntanetap significantly improves cognition in all Parkinson’s patients, with those exhibiting Alzheimer’s co-pathology showing a three-times greater response New data demonstrate reductions in plasma biomarkers pTau217, total tau, and brain-derived tau following buntanetap treatment Findings support buntanetap's potential to address cognitive decline in Parkinson's disease, show disease-modifying efficacy, and inform future clinical development MALVERN, Pa., Nov. 17, 2025 (GLOBE NEWSWIRE) -- Annovis Bio, I ...

Exhibit 99 ● Annovis' pivotal Phase 3 study in early AD (NCT06709014) remains on track, with all 84 clinical sites fully activated, recruiting, and treating participants across the U.S. ● The trial has generated robust participation, reflecting growing enthusiasm from the patient community. The screen failure rate remains within expected projections. ● The first patients have successfully completed the 6-month treatment period, a key milestone for the upcoming symptomatic readout, reinforcing steady progres ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED SEPTEMBER 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 COMMISSION FILE NUMBER 001-39202 Annovis Bio, Inc. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) Delaware ...

MALVERN, Pa., Nov. 12, 2025 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD), today provided corporate updates and third quarter 2025 financial results. "The past quarter delivered breakthrough progress on every front," said Maria Maccecchini, Ph.D., President and CEO of Annovis. "Our pivotal Phase 3 Alzhe ...

All 84 clinical sites across the U.S. are fully activated, enrolling, and treating patients The first group of participants reached the 6-month treatment milestone The study is now 25% complete, keeping Annovis on track for data readout MALVERN, Pa., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's diseas ...

Core Viewpoint - Annovis Bio, Inc. has announced a registered direct offering of 1,670,732 shares of its common stock at a price of $2.05 per share, aiming to raise approximately $3.4 million for working capital and general corporate purposes [1][2]. Group 1: Offering Details - The offering price of $2.05 per share reflects the closing price on October 24, 2025 [1]. - The total gross proceeds from the offering are expected to be around $3.4 million before deducting fees and expenses [2]. - H.C. Wainwright & Co. is acting as the exclusive placement agent for this offering [2]. Group 2: Company Background - Annovis Bio is focused on developing therapies for neurodegenerative diseases, including Alzheimer's disease (AD) and Parkinson's disease (PD) [5]. - The company is headquartered in Malvern, Pennsylvania, and is committed to improving patient outcomes and quality of life through innovative therapies [5]. Group 3: Regulatory Information - The securities are being offered under a "shelf" registration statement previously filed with the SEC, which became effective on February 12, 2024 [3]. - A prospectus supplement related to the offering will be filed with the SEC and will be available on their website [3].

Core Viewpoint - Annovis Bio, Inc. has successfully closed a registered direct offering, raising approximately $6 million to support its operations in developing therapies for neurodegenerative diseases like Alzheimer's and Parkinson's disease [1][2]. Group 1: Offering Details - The company offered 4,000,000 shares of common stock at a price of $1.50 per share [1]. - H.C. Wainwright & Co. served as the exclusive placement agent for this offering [2]. - The gross proceeds from the offering were around $6 million, which will be used for working capital and general corporate purposes [2]. Group 2: Regulatory Information - The securities were sold under a "shelf" registration statement on Form S-3, which was filed with the SEC on February 1, 2024, and declared effective on February 12, 2024 [3]. - A prospectus supplement related to the offering was filed with the SEC and is available on their website [3]. Group 3: Company Overview - Annovis Bio is headquartered in Malvern, Pennsylvania, and focuses on innovative therapies for neurodegenerative diseases [5]. - The company aims to improve patient outcomes and quality of life through its research and development efforts [5].